← Back to Clinical Trials
Recruiting NCT06635993

Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion

Trial Parameters

Condition Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion
Sponsor Qifu Li
Study Type OBSERVATIONAL
Phase N/A
Enrollment 97
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2024-08-12
Completion 2026-08-12
Interventions
68Ga-Pentixafor PET/CT

Brief Summary

To evaluate the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of primary aldosteronism concurrent with autonomous cortisol secretion patient, using AVS and/or postoperative remission as the reference standard for classification diagnosis.

Eligibility Criteria

Inclusion Criteria: 1. Getting the written informed consent 2. The clear diagnosis of primary aldosteronism; 3. Combined with autonomous cortisol secretion, cortisol after 1mg dexamethasone suppression test (DST) ≥50 nmol/l; 4. Patients who are willing to undergo surgery; 5. Adrenal CT or MRI scan of the adrenal glands with nodule (≥1cm). Exclusion Criteria: 1. PA patients who meet the by-passing AVS criteria \[i.e., younger than 35 years old, spontaneous hypokalemia, adrenal CT indicated unilateral low-density adenoma (≥1cm), plasma aldosterone \>300pg/ml\]; 2. Suspicion of familial hyperaldosteronism or Liddle syndrome. \[i.e., age \<20 years, hypertension and hypokalemia, or with family history\]; 3. Suspicion of pheochromocytoma or adrenal carcinoma; 4. Patients with actively malignant tumor; 5. Patients who have adrenalectomy history; 6. Long-term use of glucocorticoids; 7. Patients who are allergic to contrast media and cannot tolerate AVS; 8. Pregnant or lactating

Related Trials